Investors Catching Stocks Kinross Gold Corporation (KGC)

The stock of Kinross Gold Corporation (USA) (NYSE:KGC) earned "Market Perform" rating by BMO Capital Markets on Monday, December 19. Credit Suisse Group AG reissued a "hold" rating and issued a $5.00 target price on shares of Kinross Gold in a research note on Thursday, April 27th.

Among 3 analysts covering Moog (NYSE:MOG.A), 0 have Buy rating, 0 Sell and 3 Hold. Finally, CIBC upgraded shares of Kinross Gold from a "sector perform" rating to a "sector outperform" rating in a report on Wednesday, May 3rd.

Analysts have given a mean recommendation of 3.00 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

While looking at the Stock's Performance, Kinross Gold Corporation now shows a Weekly Performance of 4.95%, where Monthly Performance is -5.32%, Quarterly performance is 14.1%, 6 Months performance is 17.11% and yearly performance percentage is 20.27%.

Following trading activity for Kinross Gold Corporation (NYSE:KGC), we can see that the stock has moved onto today's list of most actives. Price Target plays a critical role when it comes to the analysis of a Stock. BMO Capital Markets' price objective indicates a potential upside of 17.92% from the stock's previous close.

Kinross Gold Corporation (NYSE:KGC) shares typically trade an average volume of 10349.62 and institutions hold 69.90% of the total shares. Kinross Gold has a one year low of $2.88 and a one year high of $5.81. The company has market cap of $5.56 billion.

Kinross Gold (NYSE:KGC) last announced its earnings results on Tuesday, May 2nd. Analysts forecast earnings per share of $0.01, down exactly $0.09 or 90.00 % from 2014's $0.1 EPS.

A statistical measure of the dispersion of returns (volatility) for FHN producing salvation in Investors mouth, it has week volatility of 1.37% and for the month booked as 1.58%.

While considering growth estimates of the company, it has next quarter growth estimates of 175% whereas during current quarter it has -80% estimations over growth, comparing to the estimations of 37.5% during current year and 9.1% for next year. The company's price to sales ratio for trailing twelve months is 0.76 and price to book ratio for most recent quarter is 1.51, whereas price to cash per share for the most recent quarter is 2.76.

Previously Kinross Gold Corp (NYSE:KGC) reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02.

Depomed, Inc. (NASDAQ:DEPO) overall volume in the last trading session was 2,337,279 shares. For the quarter, shares are performing at -7.19%. Breaking that down further, it has performed 1.62% for the week, -6.99% for the month, 15.22% over the last quarter, 14.03% for the past half-year and 22.28% for this a year ago. The stock rose 1.71% or $0.08 reaching $4.47. Capstone Asset Management Co. boosted its position in shares of Kinross Gold by 3.1% in the first quarter. The stock has "Buy" rating by Zacks on Friday, August 21. Rockshelter Capital Management LLC boosted its position in shares of Kinross Gold by 0.9% in the first quarter. The stock has "Buy" rating by TD Securities on Thursday, March 31. The Ameriprise Financial Inc holds 262,750 shares with $18.84M value, up from 218,888 last quarter. As higher figure of institutional mostly indicates intentions of capital gain, which is suitable for passive investors as well stocks with a large amount of institutional ownership are often looked upon favorably.

Like this


13 October 2017
Diego Simeone insists Barcelona are still not as good as Real Madrid
They defend as a unit and are disciplined. "I know the best way to stop him". Messi had that night that all Argentines wanted and asked for.

13 October 2017
Physicians Realty Trust (DOC) Given Average Recommendation of "Buy" by Analysts
The stock of Physicians Realty Trust (NYSE:DOC) earned "Overweight" rating by KeyBanc Capital Markets on Thursday, October 12. Short traders are more bearish on shares of Acadia Realty Trust lately if you put credence in the increase in short interest.

13 October 2017
Tamil Nadu Cabinet Approved 7th Pay Commission, Know Your New Salaries
The TFPC has cleared the roadblock for Mersal's release and the film will hit the screens on Diwali as scheduled. I don't think people would mind paying Rs 8 in addition to a Rs 100 ticket.

13 October 2017
Militant arrested in Tral, south Kashmir
"He was involved in a grenade attack at bus stand Tral in Pulwama on December 5, 2014 in which five people were killed". A case FIR number 121/2014 under section 307/RPC, 2/5 Exp.

13 October 2017
Ex-Dividend Reminder: Graham Holdings, Saul Centers and PNC Financial Services Group
Following the completion of the transaction, the insider now owns 23,820 shares of the company's stock, valued at $3,058,488. Charter Equity downgraded Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) on Wednesday, July 20 to "Mkt Underperform" rating.

13 October 2017
Shakespeare confirms Adrien Silva training with Leicester
I am still getting to know him, I do not know him 100% yet. "He's had to miss out not only on club football but worldwide football and we've tried to keep his spirits up".

13 October 2017
Commerce Bancshares Inc. Q3 Earnings Advance 9%
On August 10 the stock rating was downgraded to "Underperform" from "Market Perform" in an announcement from Raymond James. It operates through four divisions: North America, South America, Asia Pacific, and Europe, Middle East and Africa.

13 October 2017
Kitchen fumes force European Union summit site evacuation
The building has been nicknamed the "space egg" because of its interior oval shape and cost 321 million euros to build. The EU said an investigation into the incident had been launched.

13 October 2017
Mirabelli hopes Belotti will eventually join AC Milan
My daughter goes to school here. "When you write something it is important to write the truth". He said: "For two weeks I have been reading the wrong things".

13 October 2017
Brokers Opinions on: Flexion Therapeutics, Inc. (FLXN)
News articles about Flexion Therapeutics (NASDAQ: FLXN ) have been trending somewhat positive this week, Alpha One reports. ValuEngine upgraded Flexion Therapeutics from a sell rating to a hold rating in a research note on Friday, September 1st.